Clinical trial
A Phase 1/2a Trial of the Safety, Tolerability and Immunogenicity of PIV5-vectored RSV Vaccine (BLB-201) in RSV Seronegative and Seropositive Infants and Children
NCT05655182 is registered in ClinicalTrials.gov with Blue Lake Biotechnology Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2a Trial of the Safety, Tolerability and Immunogenicity of PIV5-vectored RSV Vaccine (BLB-201) in RSV Seronegative and Seropositive Infants and Children
- Lead sponsor
- Blue Lake Biotechnology Inc.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- March 9, 2023
- Completion date
- December 30, 2028
- Enrollment
- 137 (estimated)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.